|
1. Maziak, D.E., et al., Photodynamic therapy in nonsmall cell lung cancer: a systematic review. Ann Thorac Surg, 2004. 77(4): p. 1484-91. 2. Hoffman, P.C., A.M. Mauer, and E.E. Vokes, Lung cancer. Lancet, 2000. 355(9202): p. 479-85. 3. Travis, W.D., L.B. Travis, and S.S. Devesa, Lung cancer. Cancer, 1995. 75(1 Suppl): p. 191-202. 4. Bryant, A. and R.J. Cerfolio, Differences in epidemiology, histology, and survival between cigarette smokers and never-smokers who develop non-small cell lung cancer. Chest, 2007. 132(1): p. 185-92. 5. Goffin, J., et al., First-line systemic chemotherapy in the treatment of advanced non-small cell lung cancer: a systematic review. J Thorac Oncol, 2010. 5(2): p. 260-74. 6. Guo, L., et al., Characterization and immunostimulatory activity of a polysaccharide from the spores of Ganoderma lucidum. Int Immunopharmacol, 2009. 9(10): p. 1175-82. 7. Liu, G.Q. and K.C. Zhang, Enhancement of polysaccharides production in Ganoderma lucidum by the addition of ethyl acetate extracts from Eupolyphaga sinensis and Catharsius molossus. Appl Microbiol Biotechnol, 2007. 74(3): p. 572-7. 8. Ziegler, S.F., FOXP3: of mice and men. Annu Rev Immunol, 2006. 24: p. 209-26. 9. Fukuzawa, M., et al., Possible involvement of long chain fatty acids in the spores of Ganoderma lucidum (Reishi Houshi) to its anti-tumor activity. Biol Pharm Bull, 2008. 31(10): p. 1933-7. 10. Sliva, D., M.T. Rizzo, and D. English, Phosphatidylinositol 3-kinase and NF-kappaB regulate motility of invasive MDA-MB-231 human breast cancer cells by the secretion of urokinase-type plasminogen activator. J Biol Chem, 2002. 277(5): p. 3150-7. 11. Lin, S.B., et al., Triterpene-enriched extracts from Ganoderma lucidum inhibit growth of hepatoma cells via suppressing protein kinase C, activating mitogen-activated protein kinases and G2-phase cell cycle arrest. Life Sci, 2003. 72(21): p. 2381-90. 12. Jiang, J., V. Slivova, and D. Sliva, Ganoderma lucidum inhibits proliferation of human breast cancer cells by down-regulation of estrogen receptor and NF-kappaB signaling. Int J Oncol, 2006. 29(3): p. 695-703. 13. Nelson, J., et al., The endothelin axis: emerging role in cancer. Nat Rev Cancer, 2003. 3(2): p. 110-6. 14. Bagnato, A. and L. Rosano, The endothelin axis in cancer. Int J Biochem Cell Biol, 2008. 40(8): p. 1443-51. 15. Bagnato, A., F. Spinella, and L. Rosano, The endothelin axis in cancer: the promise and the challenges of molecularly targeted therapy. Can J Physiol Pharmacol, 2008. 86(8): p. 473-84. 16. Zhang, W.M., J. Zhou, and Q.J. Ye, Endothelin-1 enhances proliferation of lung cancer cells by increasing intracellular free Ca2+. Life Sci, 2008. 82(13-14): p. 764-71. 17. Bagnato, A., F. Spinella, and L. Rosano, Emerging role of the endothelin axis in ovarian tumor progression. Endocr Relat Cancer, 2005. 12(4): p. 761-72. 18. Yarden, Y. and M.X. Sliwkowski, Untangling the ErbB signalling network. Nat Rev Mol Cell Biol, 2001. 2(2): p. 127-37. 19. Zwick, E., et al., The EGF receptor as central transducer of heterologous signalling systems. Trends Pharmacol Sci, 1999. 20(10): p. 408-12. 20. Hynes, N.E. and H.A. Lane, ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer, 2005. 5(5): p. 341-54. 21. Citri, A. and Y. Yarden, EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol, 2006. 7(7): p. 505-16. 22. Nyati, M.K., et al., Integration of EGFR inhibitors with radiochemotherapy. Nat Rev Cancer, 2006. 6(11): p. 876-85. 23. Vivanco, I. and C.L. Sawyers, The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer, 2002. 2(7): p. 489-501. 24. Moon, R.T., et al., WNT and beta-catenin signalling: diseases and therapies. Nat Rev Genet, 2004. 5(9): p. 691-701. 25. Corder, R., et al., Endothelin-1 synthesis reduced by red wine. Nature, 2001. 414(6866): p. 863-4. 26. Spinella, F., et al., Green tea polyphenol epigallocatechin-3-gallate inhibits the endothelin axis and downstream signaling pathways in ovarian carcinoma. Mol Cancer Ther, 2006. 5(6): p. 1483-92. 27. Rosano, L., et al., ZD4054, a specific antagonist of the endothelin A receptor, inhibits tumor growth and enhances paclitaxel activity in human ovarian carcinoma in vitro and in vivo. Mol Cancer Ther, 2007. 6(7): p. 2003-11. 28. Rosano, L., et al., Combined targeting of endothelin A receptor and epidermal growth factor receptor in ovarian cancer shows enhanced antitumor activity. Cancer Res, 2007. 67(13): p. 6351-9. 29. Kuo, P.L., Y.L. Hsu, and C.Y. Cho, Plumbagin induces G2-M arrest and autophagy by inhibiting the AKT/mammalian target of rapamycin pathway in breast cancer cells. Mol Cancer Ther, 2006. 5(12): p. 3209-21. 30. Freedman, V.H. and S.I. Shin, Cellular tumorigenicity in nude mice: correlation with cell growth in semi-solid medium. Cell, 1974. 3(4): p. 355-9. 31. Shin, S.I., et al., Tumorigenicity of virus-transformed cells in nude mice is correlated specifically with anchorage independent growth in vitro. Proc Natl Acad Sci U S A, 1975. 72(11): p. 4435-9. 32. Buchanan, F.G., et al., Role of beta-arrestin 1 in the metastatic progression of colorectal cancer. Proc Natl Acad Sci U S A, 2006. 103(5): p. 1492-7. 33. Vacca, F., et al., Transactivation of the epidermal growth factor receptor in endothelin-1-induced mitogenic signaling in human ovarian carcinoma cells. Cancer Res, 2000. 60(18): p. 5310-7. 34. Bagnato, A. and P.G. Natali, Endothelin receptors as novel targets in tumor therapy. J Transl Med, 2004. 2(1): p. 16. 35. Chang, F., et al., Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. Leukemia, 2003. 17(3): p. 590-603. 36. Soo, R.A., et al., First-line systemic treatment of advanced stage non-small-cell lung cancer in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol, 2009. 10(11): p. 1102-10. 37. Boldrini, L., et al., Expression of endothelin-1 is related to poor prognosis in non-small cell lung carcinoma. Eur J Cancer, 2005. 41(18): p. 2828-35. 38. Ahmed, S.I., et al., Studies on the expression of endothelin, its receptor subtypes, and converting enzymes in lung cancer and in human bronchial epithelium. Am J Respir Cell Mol Biol, 2000. 22(4): p. 422-31. 39. Sharma, S.V., et al., Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer, 2007. 7(3): p. 169-81. 40. Thomas, S.M., et al., Cross-talk between G protein-coupled receptor and epidermal growth factor receptor signaling pathways contributes to growth and invasion of head and neck squamous cell carcinoma. Cancer Res, 2006. 66(24): p. 11831-9. 41. Daub, H., et al., Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors. Nature, 1996. 379(6565): p. 557-60. 42. Luttrell, L.M., et al., Gbetagamma subunits mediate Src-dependent phosphorylation of the epidermal growth factor receptor. A scaffold for G protein-coupled receptor-mediated Ras activation. J Biol Chem, 1997. 272(7): p. 4637-44. 43. Prenzel, N., et al., EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature, 1999. 402(6764): p. 884-8. 44. Filardo, E.J., et al., Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF. Mol Endocrinol, 2000. 14(10): p. 1649-60. 45. Lattin, J., et al., G-protein-coupled receptor expression, function, and signaling in macrophages. J Leukoc Biol, 2007. 82(1): p. 16-32. 46. Michael, J.B., et al., Drug therapy of lung cancer. Aust. Pre, 2003. 26(5): p. 103-105. 47. M. Zhang, et al., Antitumor Polysaccharides from mushrooms: a review on their isolation process, stractural characteritics and antitumor activities. Trend in food science & Techonology, 2007 18: p. 4-9
|